4-phenylbutyric acid has been researched along with Orphan Diseases in 2 studies
4-phenylbutyric acid: RN refers to the parent cpd
4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.
Orphan Diseases: Rare diseases that have not been well studied.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Four Phase 1 studies were conducted to characterize the bioavailability (BA) and/or bioequivalence (BE) of ACER-001 (in healthy volunteers) and taste assessment relative to NaPBA powder (in taste panelists)." | 1.91 | Taste-masked formulation of sodium phenylbutyrate (ACER-001) for the treatment of urea cycle disorders. ( Cederbaum, SD; Edwards, J; Kellmeyer, T; Peters, Y; Steiner, RD, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cederbaum, SD | 1 |
| Edwards, J | 1 |
| Kellmeyer, T | 1 |
| Peters, Y | 1 |
| Steiner, RD | 1 |
| Vanhoorne, V | 1 |
| Peeters, E | 1 |
| Van Tongelen, I | 1 |
| Boussery, K | 1 |
| Wynendaele, E | 1 |
| De Spiegeleer, B | 1 |
| Remon, JP | 1 |
| Vervaet, C | 1 |
2 other studies available for 4-phenylbutyric acid and Orphan Diseases
| Article | Year |
|---|---|
Taste-masked formulation of sodium phenylbutyrate (ACER-001) for the treatment of urea cycle disorders.
Topics: Humans; Hyperammonemia; Nitrogen; Phenylbutyrates; Powders; Rare Diseases; Taste; Urea; Urea Cycle D | 2023 |
Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases.
Topics: Arginine; Belgium; Carnitine; Drug Compounding; Excipients; Humans; Pharmacists; Phenylbutyrates; Pr | 2019 |